Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Crescent Biopharma, Inc. entered into an underwriting agreement for an underwritten public offering of ordinary shares and pre-funded warrants. The company is issuing 8,094,793 ordinary shares at $14.50 per share and, for certain investors, pre-funded warrants to purchase an aggregate of 525,897 ordinary shares at $14.499 per warrant.
The underwriters have a 30-day option to buy up to 1,293,103 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds are expected to be approximately $125.0 million, with estimated net proceeds of about $115.9 million, or $133.5 million if the option is fully exercised. The offering is expected to close on July 16, 2026, subject to customary conditions.
Each pre-funded warrant has a $0.001 exercise price, is immediately exercisable, does not expire, and includes beneficial ownership limitations of 4.99%, 9.99% or 19.99%. Crescent expects the net proceeds, together with existing cash, to fund operating, working capital and capital expenditure needs into the second half of 2028.
Positive
- None.
Negative
- None.
Filing Explained
The deal is signed but not closed; completion would add shares or warrant-linked shares, reducing existing holders’ percentage ownership.
Form 8-K reports specified material events; this filing reports that Crescent Biopharma signed and priced an underwritten offering on
The offering was not yet closed: it covered 8,094,793 ordinary shares or, for certain investors, pre-funded warrants for 525,897 shares; shares issued at closing and shares later issued on warrant exercise would increase the share count and reduce existing holders’ percentage ownership absent offsets.
An underwritten offering is one in which investment banks buy securities from the issuer for resale. The pre-funded warrants are immediately exercisable, have a
Although the commencement exhibit described the transaction as proposed, the later pricing disclosure and the 8-K state that the underwriting agreement had been entered into and terms fixed; completion remained subject to customary closing conditions.
The filing identifies
Sources and calculations
- Crescent Biopharma Form 8-K with Exhibits 99.1 and 99.2 (2026-07-14)
- Form 8-K purpose (2026-07-14)
- Dilution definition (2026-07-14)
- Underwritten offering definition (2026-07-14)
- Pre-funded warrant definition (2026-07-14)
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Ordinary shares offered: 8,094,793 shares
Pre-funded warrants offered: 525,897 warrants
Underwriters’ option shares: 1,293,103 shares
+5 more
8 metrics
Ordinary shares offered
8,094,793 shares
Public offering of ordinary shares at $14.50 per share
Pre-funded warrants offered
525,897 warrants
Pre-funded warrants sold at $14.499 per warrant in lieu of shares to certain investors
Underwriters’ option shares
1,293,103 shares
30-day option to purchase additional ordinary shares at the public offering price less discounts
Gross proceeds
approximately $125.0 million
Expected gross proceeds before underwriting discounts and expenses
Net proceeds (base deal)
approximately $115.9 million
Estimated net proceeds to Crescent excluding any exercise of the underwriters’ option
Net proceeds (with option)
approximately $133.5 million
Estimated net proceeds if the underwriters’ option to purchase additional shares is exercised in full
Pre-funded warrant exercise price
$0.001 per share
Exercise price for each pre-funded warrant, immediately exercisable and non-expiring
Runway estimate
into the second half of 2028
Expected period that net proceeds plus existing cash will fund operations and capital needs
Key Terms
underwritten public offering, Pre-Funded Warrants, shelf registration statement on Form S-3, beneficial ownership limitation, +1 more
5 terms
underwritten public offering financial
"entered into an underwriting agreement ... relating to the issuance and sale in a public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
Pre-Funded Warrants financial
"pre-funded warrants to purchase an aggregate of 525,897 Ordinary Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shelf registration statement on Form S-3 regulatory
"The offering is being made pursuant to the Company’s shelf registration statement on Form S-3"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
beneficial ownership limitation financial
"to own more than a specified beneficial ownership limitation of either 4.99%, 9.99% or 19.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
fundamental transactions financial
"In the event of certain fundamental transactions (as described in the Pre-Funded Warrants)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is Crescent Biopharma (CBIO) raising in its July 2026 equity offering?
Crescent Biopharma is selling 8,094,793 ordinary shares and pre-funded warrants for 525,897 shares, priced at $14.50 and $14.499, respectively. The company expects gross proceeds of about $125.0 million and net proceeds of about $115.9 million, or $133.5 million with the option exercised.
What are the key terms of Crescent Biopharma (CBIO) pre-funded warrants in this deal?
Crescent’s pre-funded warrants cover 525,897 ordinary shares, are sold at $14.499 each and have a $0.001 exercise price. They are immediately exercisable, do not expire, and include beneficial ownership limits of 4.99%, 9.99% or 19.99%, adjustable with 61 days’ notice.
How much cash runway does Crescent Biopharma (CBIO) expect from this financing?
Crescent expects the net proceeds of about $115.9 million (or $133.5 million if the underwriters’ option is fully exercised), together with existing cash and cash equivalents, to fund projected operating expenses, working capital and capital expenditures into the second half of 2028, based on current assumptions.
What is the underwriters’ option in Crescent Biopharma (CBIO) offering?
Under the underwriting agreement, Crescent granted the underwriters a 30-day option to purchase up to 1,293,103 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Any additional shares would increase Crescent’s total net proceeds from the transaction.
When is Crescent Biopharma (CBIO) expecting the offering to close?
Crescent expects the underwritten public offering of ordinary shares and pre-funded warrants to close on July 16, 2026, subject to the satisfaction of customary closing conditions. Until those conditions are met, there is no assurance the transaction will be completed as planned.
Under what registration statement is Crescent Biopharma (CBIO) conducting this offering?
The securities are being offered under Crescent’s shelf registration statement on Form S-3 (Registration No. 333-297199), which was declared effective by the SEC on July 10, 2026. A prospectus supplement and accompanying prospectus govern the specific terms of this offering.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________________________________________________
FORM 8-K
________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 14, 2026
________________________________________________________________________________________________
(Exact Name of Registrant as Specified in Charter)
________________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (617 ) 430-5595
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||||||||
The | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events.
On July 14, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of (i) 8,094,793 of the Company’s ordinary shares, par value US$0.001 per share (the "Ordinary Shares," and such Ordinary Shares being offered, the "Shares"), at an offering price to the public of $14.50 per Share, and (ii) with respect to certain investors, in lieu of Ordinary Shares, pre-funded warrants to purchase an aggregate of 525,897 Ordinary Shares at a price to the public of $14.499 per pre-funded warrant (the “Pre-Funded Warrants”), which represents the per share price for the Shares less a nominal $0.001 per share exercise price for each Pre-Funded Warrant. The Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $13.63 per share and Pre-Funded Warrants at a price of $13.629 per pre-funded warrant. In addition, under the terms of the Underwriting Agreement, the Company has granted the Underwriters a 30-day option to purchase up to 1,293,103 additional Ordinary Shares at the public offering price, less underwriting discounts and commissions. All of the Shares and Pre-Funded Warrants are being sold by the Company. The net proceeds to the Company from this offering are expected to be approximately $115.9 million, or approximately $133.5 million if the Underwriters’ option to purchase additional shares is exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 16, 2026, subject to the satisfaction of customary closing conditions.
Each Pre-Funded Warrant will have an exercise price of $0.001, will be immediately exercisable on the date of issuance and will not expire. Under the terms of the Pre-Funded Warrants, the Company may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, which, upon giving effect to such exercise, would cause a holder (together with its affiliates) to own more than a specified beneficial ownership limitation of either 4.99%, 9.99% or 19.99% (as selected by such holder prior to the issuance of the Pre-Funded Warrant) of the number of Ordinary Shares outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company.
The exercise price and the number of Ordinary Shares issuable upon exercise of each Pre-Funded Warrant will be subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Ordinary Shares.
In the event of certain fundamental transactions (as described in the Pre-Funded Warrants), a holder of Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or property that such holder would have received had they exercised in full the Pre-Funded Warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the Pre-Funded Warrants.
Based on the Company’s planned use of the net proceeds of this offering and its existing cash and cash equivalents, the Company estimates that such funds will be sufficient to enable it to fund our projected operating expenses, working capital and capital expenditure needs into the second half of 2028. This estimate is based on assumptions that may prove to be incorrect, and the Company could utilize available capital resources sooner than expected.
The offering is being made pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-297199), including the prospectus included therein, previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”), and a prospectus supplement and the accompanying prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.
The foregoing description of the Underwriting Agreement and the Pre-Funded Warrants is not complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement and form of Pre-Funded Warrant, copies of which are filed as Exhibit 1.1 and Exhibit 4.1, respectively, to this report and which are incorporated by reference herein. A copy of the opinion of Walkers (Cayman) LLP, relating to the validity under Cayman Islands law of the issuance and sale of the
Shares and a copy of the opinion of Latham & Watkins LLP, relating to the legality of the issuance and sale of the Pre-Funded Warrants in this offering are attached as Exhibit 5.1 and Exhibit 5.2, respectively, to this report.
The Company issued press releases on July 14, 2026 announcing the commencement and pricing of the offering, which press releases are attached as Exhibits 99.1 and 99.2, respectively, to this report.
Forward-Looking Statements
The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the completion of the offering, including the anticipated closing date, the exercise of the Underwriters’ option to purchase additional shares, the expected net proceeds from the offering and the anticipated use thereof. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in the Company’s business, including those described in the Company’s prior filings with the SEC, including under the heading “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2025, its quarterly report on Form 10-Q for the quarter ended March 31, 2026, and any subsequent filings with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | |||||||
| 1.1 | Underwriting Agreement, dated July 14, 2026, by and among Crescent Biopharma, Inc. and Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein | |||||||
| 4.1 | Form of Pre-Funded Warrant | |||||||
| 5.1 | Opinion of Walkers (Cayman) LLP | |||||||
| 5.2 | Opinion of Latham & Watkins LLP | |||||||
| 23.1 | Consent of Walkers (Cayman) LLP (included in Exhibit 5.1) | |||||||
| 23.2 | Consent of Latham & Watkins LLP (included in Exhibit 5.2) | |||||||
| 99.1 | Press Release, dated July 14, 2026 | |||||||
| 99.2 | Press Release, dated July 14, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CRESCENT BIOPHARMA, INC. | ||||||||||||||
| Date: July 15, 2026 | By: | /s/ Joshua Brumm | ||||||||||||
| Name: | Joshua Brumm | |||||||||||||
| Title: | Chief Executive Officer | |||||||||||||
Exhibit 99.1
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Waltham, Mass., July 14, 2026 — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has commenced an underwritten public offering of its ordinary shares or, in lieu of ordinary shares to investors that so choose, pre-funded warrants to purchase its ordinary shares. In addition, Crescent intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares at the public offering price, less underwriting discounts and commissions. All of the ordinary shares and pre-funded warrants to be sold in the proposed offering are being offered by Crescent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as passive book-running manager for the proposed offering.
The securities described above are being offered by Crescent pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 10, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus can be accessed through the SEC’s website at www.sec.gov. Copies of the prospectus supplement relating to the proposed offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors.
Forward-Looking Statements
Crescent cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the completion, timing and size of the proposed offering, and the grant of the option to purchase additional ordinary shares. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, our quarterly report on Form 10-Q for the quarter ended March 31, 2026, and any subsequent current reports on Form 8-K or other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
Exhibit 99.2
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Waltham, Mass., July 14, 2026 — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares are being sold to the public at a price of $14.50 per share and the pre-funded warrants are being sold at a price to the public of $14.499 per pre-funded warrant, which represents the per ordinary share price less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Crescent from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Crescent, are expected to be approximately $125.0 million. In addition, Crescent has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 ordinary shares at the offering price, less underwriting discounts and commissions. All of the ordinary shares and the pre-funded warrants to be sold in the public offering are to be sold by Crescent. The offering is expected to close on July 16, 2026, subject to the satisfaction of customary closing conditions.
Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering. LifeSci Capital is acting as passive book-running manager for the offering.
The securities described above are being offered by Crescent pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 10, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus once filed will be accessible through the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially
transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors.
Forward-Looking Statements
Crescent cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the expected closing of the offering and the potential exercise of the option to purchase additional ordinary shares. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, our quarterly report on Form 10-Q for the quarter ended March 31, 2026, and any subsequent current reports on Form 8-K or other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019